Stock·NASDAQ·Financial Services
CME Group Inc. (CME)
- Market cap
- $105.05B
- P/E
- 24.06
- Dividend yield
- 3.85%
- Street target
- $328.50median of 17 analysts
- 52-week range
- $218.31 $329.16
CME stock forecast today
Where CME stands today, and what CleaRank Financial AI makes of it.
CME at a glance
CME Group Inc. (CME): Buy, 63/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($278.65 and $279.76).
- Earnings CME beat estimates in 4 of the 6 reports in our data, and the stock rose the next day every time.
- Insiders Insiders sold $37.9M and bought $666K over the last 18 months.
- Valuation P/E of 24.1 against 16.5 for the Financial Services sector: a premium to peers (+46%).
Figures as of October 27, 2026.
CleaRank Financial AI
CME Group Inc. (CME) carries a CleaRank rating of Buy and a model score of 63/100.
Trend adds the most to that score, with the price 4.90% above its 200-day average and 5.32% above its 50-day average. Valuation takes the most away: the P/E of 24.06 is 45.8% above the sector median (a premium to peers), and the P/S of 15.10 is 297.4% above the sector median. The 50-day average is $278.65 and the 200-day average is $279.76, and over the past year the price climbed 8.26%.
Only on CleaRank
Figures we compute ourselves from CME's own price, earnings and insider-filing history. Tap one to see it in context.
CME stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $293.48 is 5.3% above the 50-day simple moving average of $278.65.Price above its 200-day average ›
The price is 4.9% above the 200-day simple moving average of $279.76.50-day average above the 200-day ›
The 50-day average ($278.65) is 0.4% below the 200-day average ($279.76), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 68% of its 52-week range, between $218.31 and $329.16.
CME share price
Pick a period: each tab shows how far CME has moved over it, to the last close.
Today's trading
Where CME sits inside today's range and its 52-week range.
CME fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
3/5P/E below the sector median ›
The trailing P/E of 24.06 is 45.8% above the Financial Services median of 16.5.P/S below the sector median ›
The price-to-sales ratio of 15.10 is 297.4% above the sector median of 3.8.Profitable over the last 12 months ›
Net income over the last 12 months was $4.4B on revenue of $7.0B, a net margin of 63.3%.Beat estimates in most recent reports ›
CME beat the EPS estimate in 4 of the 6 reports in our data.Pays a dividend ›
The trailing dividend yield is 3.85%, or $11.30 a share a year.
Key statistics
The headline figures for CME.
As of October 27, 2026, CME trades at $293.48, with a market value of $105.05B, a P/E ratio of 24.06 and a dividend yield of 3.85%.
What the numbers say
CleaRank Financial AI's reading of CME's valuation, growth and risks.
At 24.06 times trailing earnings, CME Group Inc. (CME) trades 45.8% above the Financial Services median P/E of 16.5, and the peer comparison on this page labels that multiple a premium to peers. Measured against sales, the P/S of 15.10 is 297.4% above the sector median of 3.8. The company carries a market value of $105.0B, and its trailing earnings stand at $12.20 per share.
CME turns sales into profit at a net margin of 63.48% and an operating margin of 65.85%, alongside a return on equity of 16.13%, above the sector median of 13.8%. Debt-to-equity of 0.15 and a trailing dividend yield of 3.85% ($11.30 a share a year) round out the fundamentals.
CME's October 21, 2026 earnings report topped expectations by 1.00%, with EPS coming in at $3.02 versus an estimate of $2.99. The shares climbed 3.45% in the following session.
Over the 6 reports in our data, CME topped the estimate 4 times, and the stock rose in the first session after each of those beats. The consensus EPS estimate stands at $12.41 for this fiscal year and $13.21 for next, growth of 10.8% for the current year.
A high valuation narrows the room for mistakes. The P/E of 24.06 sits 45.8% above the sector median, which the peer benchmarking labels a premium to peers. CME moves an average of 1.67% a day, and its beta against the S&P 500 is 0.27.
CME against the Financial Services sector
How CME compares with the median Financial Services stock CleaRank tracks.
Price to earnings vs sector: CME trades at a significant premium to sector peers (+46%), suggesting market expectations for superior growth or market position.
Return vs XLF: Since May 15, 2025, CME has gained 7.1% against a gain of 9.0% for XLF.
Performance against XLF
CME and the Financial Services sector fund over the same days.
Revenue and earnings
How much CME sells, and how much of it becomes profit.
The quarterly bars end with Q2 '26 (the quarter to June 30, 2026); CME reported again on October 21, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue grew 6.4% in FY2025 to $6.5B, from $6.1B a year earlier.
Profit margin: The net margin was 62.5% in FY2025, up from 57.5% the year before.
Profitable: CME earned $4.1B in FY2025.
Earnings reality check
Did CME beat what analysts expected, and how did the stock react?
Earnings record: CME beat the analyst estimate in 4 of the 6 reports in our data.
Market reaction: The stock rose in the first session after every beat.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 21, 2026after close | $2.99 | $3.02 | +1.00% | +3.45% | - |
| Apr 22, 2026after close | $3.37 | $3.36 | -0.30% | -0.08% | +0.55% |
| Feb 4, 2026after close | $2.74 | $2.77 | +1.09% | +0.94% | +2.67% |
| Jul 23, 2025after close | $2.92 | $2.96 | +1.37% | +0.25% | +0.46% |
| Apr 23, 2025after close | $2.81 | $2.80 | -0.36% | +0.68% | +5.97% |
| Feb 12, 2025after close | $2.45 | $2.52 | +2.86% | +0.46% | -0.26% |
As of October 27, 2026, CME has beaten the analyst EPS estimate in 4 of the 6 reports in our data and rose in the first trading session after every one of those beats; its latest report, on October 21, 2026, came in 1.00% above the estimate and the stock moved +3.45% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
CME AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 58.0, in neutral territory.RSI above 50 ›
An RSI of 58.0 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of CME
The score, the reasoning behind it, and what could move the price next.
CME is in an uptrend. Its price of $293.48 sits 4.90% above the 200-day average of $279.76 and 5.32% above the 50-day average of $278.65. Within the 52-week range, which spans $218.31 to $329.16, the stock currently sits at 68% of the way up.
The price is up over each of these periods: 10.96% over the past month, 12.88% over the past three months and 8.26% over the past year. The price fell 4.73% in the last session on volume 25.1% below its average. On momentum, the 14-day RSI reads 58.0, in the neutral zone, with the MACD line positive.
Earnings beat ›
The October 21, 2026 report beat the EPS estimate by 1.00%, and the share price rose 3.45% in the first session after it.
Source: Earnings report, October 21, 2026Analyst upgrade ›
JP Morgan upgraded it to Overweight from Underweight on October 22, 2026.
Source: Analyst action, JP Morgan, October 22, 2026
Rating reaffirmed ›
UBS kept its Neutral rating on October 22, 2026.
Source: Analyst action, UBS, October 22, 2026
- The two closest levels to keep an eye on are the 52-week high at $329.16, above the price, and the 20-day EMA at $288.56, below it.
- The 14-day RSI reads 58.0, in the neutral zone, with the MACD line positive; readings above 70 or below 30 mark stretched momentum.
- CME's share price gained 3.45% in the first session after the October 21, 2026 report, and the company has beaten estimates in 4 of the 6 reports in our data.
CME is trading above its 50-day and 200-day moving averages ($278.65 and $279.76), and that keeps the trend up. A drop through the 200-day average would be the first sign of weakness. The closest support below the price is the 20-day EMA, at $288.56.
Overhead, the next level the price would meet is the 52-week high at $329.16.
Technical indicators
Momentum and trend for CME, from its daily closes.
As of October 27, 2026, with CME at $293.48, its 14-day RSI is 58.0 (neutral territory), its 50-day simple moving average is $278.65 and its 200-day is $279.76.
Calculated by CleaRank on daily closes as of October 27, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What CME moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 27, 2026, CME's 1-year correlation of daily returns is -0.10 with S&P 500 (SPY), -0.20 with Nasdaq 100 (QQQ), +0.01 with Bitcoin (BTC) and +0.00 with gold (XAU).
CME price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
9 of 17 analysts rate it a buy or strong buy, 6 a hold and 2 a sell.Median target above the price ›
The median 12-month target of $328.50 is 11.9% above the price.More buy ratings than three months ago ›
9 of 17 rate it a buy now, against 9 of 16 three months ago.
CME Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 22, 2026 | UBS | Maintains | Neutral |
| Oct 22, 2026 | Morgan Stanley | Maintains | Overweight |
| Oct 22, 2026 | Barclays | Maintains | Equal-Weight |
| Oct 22, 2026 | Wells Fargo | Maintains | Overweight |
| Oct 22, 2026 | Piper Sandler | Reiterates | Overweight |
| Oct 22, 2026 | JP Morgan | Upgrade | Overweight |
As of October 27, 2026, 17 Wall Street analysts cover CME: 9 rate it a buy or strong buy, 6 a hold and 2 a sell or strong sell. Their 12-month price targets range from $227.00 to $367.00. The median CME price target is $328.50, 11.9% above the price of $293.48.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
CME trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
CME trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from CME's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much CME tends to move, against the market and on its own.
CME price history and drawdowns
CME's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
4/4Average daily move under 2% ›
The price has moved 1.67% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 35.8%, from March 2020 to March 2020, regained by May 2021.Most 1-year holds ended higher ›
77% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $42,947, against $42,376 in the S&P 500 (SPY).
CME Drawdowns & Recovery
As of October 27, 2026, CME's worst peak-to-trough fall over the last 10 years with dividends reinvested was -35.8% (March 2020 to March 2020); it regained that peak by May 2021, 14 months after the low, and 77% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CME in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: CME beat the S&P 500 over this period: $42,947 against $42,376.
A $10,000 investment in CME in October 2016 would be worth about $42,947 today with dividends reinvested, compared with about $42,376 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to CME, and which have not.
Strongest month, February: an average of +5.06%, up in 10 of 10 years.
Weakest month, March: an average of -2.62%, up in 5 of 10 years.
This month, October: has averaged +1.61%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, CME's strongest calendar month has been February (average +5.06%, up in 10 of 10 years) and its weakest March (average -2.62%, up in 5 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
CME stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CME, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in CME today could grow to about $13,713 by 2030 in the base case, with a 90th-percentile outcome near $25,802 and a 10th-percentile outcome around $7,288. The simulation models price only; at today's 3.85% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
CME Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $402 for CME by 2030 in the base case, from $293 today (1.4x over 4 years). The 10th-percentile path ends near $214. These are outcomes of a Monte Carlo simulation run on CME's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $232 | $318 | $436 | |
| 2028 | $220 | $344 | $537 | |
| 2029 | $215 | $372 | $643 | |
| 2030 | $214 | $402 | $757 |
Method: a lognormal simulation of CME's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
CME insider trading
What the people running the company have bought and sold.
CME insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $666K on the open market and sold $37.9M.
As of October 27, 2026, CME insiders reported 27 open-market sales worth $37.9M and 4 open-market purchases worth $666K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 22, 2026 | Martin J Gepsman
Director
|
Sell | 400 | $121.0K |
| Sep 25, 2026 | William R Shepard
Director
|
Buy | 292 | $78.6K |
| Sep 15, 2026 | Derek Louis Sammann
Officer
|
Grant | 2.9K | $787.9K |
| Sep 15, 2026 | Kendal L Vroman
Officer
|
Grant | 2.6K | $713.0K |
| Sep 14, 2026 | Elizabeth A Cook
Director
|
Sell | 500 | $140.1K |
| Sep 10, 2026 | Terrence A Duffy
Chief Executive Officer
|
Sell | 15.0K | $4.1M |
| Jun 25, 2026 | Kathryn Benesh
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Timothy S Bitsberger
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Charles P Carey
Director
|
Grant | 1.1K | $240.1K |
| Jun 25, 2026 | Elizabeth A Cook
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Bryan T Durkin
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Harold Eugene Ford Jr
Director
|
Grant | 1.1K | $240.1K |
| Jun 25, 2026 | Martin J Gepsman
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | William W Hobert
Director
|
Grant | 1.1K | $240.1K |
| Jun 25, 2026 | Daniel G Kaye
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Phyllis M Lockett
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Deborah J Lucas
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Patrick W Maloney
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Patrick J Mulchrone
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Rahael Seifu
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | William R Shepard
Director
|
Grant | 1.1K | $240.1K |
| Jun 25, 2026 | William R Shepard
Director
|
Buy | 339 | $78.2K |
| Jun 25, 2026 | Howard J Siegel
Director
|
Grant | 1.1K | $240.1K |
| Jun 25, 2026 | Dennis A. Suskind
Director
|
Grant | 645 | $145.1K |
| Jun 25, 2026 | Robert J. Tierney Jr
Director
|
Grant | 645 | $145.1K |
| May 18, 2026 | Hilda Harris Piell
Officer
|
Sell | 5.8K | $1.8M |
| May 15, 2026 | Terrence A Duffy
Chief Executive Officer
|
Sell | 35.0K | $10.4M |
| Mar 26, 2026 | William R Shepard
Director
|
Buy | 1.5K | $437.1K |
| Mar 17, 2026 | Jonathan L Marcus
General Counsel
|
Sell | 3.3K | $1.1M |
| Mar 17, 2026 | Jonathan L Marcus
Officer
|
Sell | 3.3K | $1.0M |
| Mar 13, 2026 | Sunil Kiran Cutinho
Chief Technology Officer
|
Grant | 8.3K | $2.6M |
| Mar 13, 2026 | Terrence A Duffy
Chief Executive Officer
|
Grant | 62.9K | $19.6M |
| Mar 13, 2026 | Lynne Fitzpatrick
Chief Executive Officer
|
Grant | 5.5K | $1.7M |
| Mar 13, 2026 | Jonathan L Marcus
General Counsel
|
Grant | 5.3K | $1.6M |
| Mar 13, 2026 | Timothy Francis Mccourt
Officer
|
Grant | 5.5K | $1.7M |
| Mar 13, 2026 | Hilda Harris Piell
Officer
|
Grant | 7.1K | $2.2M |
| Mar 13, 2026 | Derek Louis Sammann
Officer
|
Grant | 8.3K | $2.6M |
| Mar 13, 2026 | Suzanne Sprague
Chief Operating Officer
|
Grant | 5.5K | $1.7M |
| Mar 13, 2026 | Jack J Tobin
Officer
|
Grant | 608 | $189.3K |
| Mar 13, 2026 | Kendal L Vroman
Officer
|
Grant | 7.1K | $2.2M |
| Mar 13, 2026 | Julie Winkler
Officer
|
Grant | 8.3K | $2.6M |
| Mar 12, 2026 | Kendal L Vroman
Officer
|
Sell | 5.2K | $1.6M |
| Mar 11, 2026 | Jack J Tobin
Officer
|
Grant | 105 | - |
| Mar 6, 2026 | Elizabeth A Cook
Director
|
Sell | 1.0K | $320.0K |
| Feb 23, 2026 | Bryan T Durkin
Director
|
Sell | 4.2K | $1.3M |
| Feb 20, 2026 | Martin J Gepsman
Director
|
Sell | 300 | $91.8K |
| Feb 6, 2026 | Dennis A Suskind
Director
|
Sell | 748 | $224.4K |
| Dec 11, 2025 | Terrence A Duffy
Chief Executive Officer
|
Sell | 25.0K | $6.7M |
| Nov 20, 2025 | Derek Louis Sammann
Officer
|
Sell | 7.2K | $2.0M |
| Nov 7, 2025 | Hilda Harris Piell
Officer
|
Grant | 973 | - |
| Nov 3, 2025 | Harold Eugene Ford Jr
Director
|
Sell | 1.0K | $263.5K |
| Sep 18, 2025 | Jonathan L Marcus
General Counsel
|
Sell | 392 | $102.7K |
| Sep 16, 2025 | Timothy Francis Mccourt
Officer
|
Sell | 379 | $98.5K |
| Sep 16, 2025 | Jonathan L Marcus
General Counsel
|
Sell | 376 | $97.4K |
| Sep 15, 2025 | Sunil Kiran Cutinho
Chief Technology Officer
|
Grant | 3.0K | $787.9K |
| Sep 15, 2025 | Michael G Dennis
Officer
|
Grant | 2.6K | $675.0K |
| Sep 15, 2025 | Terrence A Duffy
Chief Executive Officer
|
Grant | 23.2K | $6.0M |
| Sep 15, 2025 | Lynne Fitzpatrick
President
|
Grant | 4.3K | $1.1M |
| Sep 15, 2025 | Jonathan L Marcus
General Counsel
|
Grant | 2.5K | $637.8K |
| Sep 15, 2025 | Timothy Francis Mccourt
Officer
|
Grant | 2.8K | $712.3K |
| Sep 15, 2025 | Hilda Harris Piell
Officer
|
Grant | 2.6K | $675.0K |
| Sep 15, 2025 | Derek Louis Sammann
Officer
|
Grant | 3.0K | $787.9K |
| Sep 15, 2025 | Suzanne Sprague
Officer
|
Grant | 3.0K | $787.9K |
| Sep 15, 2025 | Jack J Tobin
Officer
|
Grant | 1.5K | $400.2K |
| Sep 15, 2025 | Kendal L Vroman
Chief Technology Officer
|
Grant | 2.6K | $675.0K |
| Sep 15, 2025 | Julie Winkler
Officer
|
Grant | 3.0K | $787.9K |
| Aug 26, 2025 | Sunil Kiran Cutinho
Chief Technology Officer
|
Sell | 11.9K | $3.2M |
| Jun 25, 2025 | Kathryn Benesh
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Timothy S Bitsberger
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Charles P Carey
Director
|
Grant | 879 | $240.0K |
| Jun 25, 2025 | Elizabeth A Cook
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Bryan T Durkin
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Harold Eugene Ford Jr
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Martin J Gepsman
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | William W Hobert
Director
|
Grant | 879 | $240.0K |
| Jun 25, 2025 | Daniel G Kaye
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Phyllis M Lockett
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Deborah J Lucas
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Patrick W Maloney
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Patrick J Mulchrone
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Rahael Seifu
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | William R Shepard
Director
|
Grant | 879 | $240.0K |
| Jun 25, 2025 | William R Shepard
Director
|
Buy | 267 | $72.3K |
| Jun 25, 2025 | Howard J Siegel
Director
|
Grant | 879 | $240.0K |
| Jun 25, 2025 | Dennis A Suskind
Director
|
Grant | 532 | $145.3K |
| Jun 25, 2025 | Robert J. Tierney Jr
Director
|
Grant | 532 | $145.3K |
| Jun 10, 2025 | Charles P Carey
Director
|
Sell | 500 | $132.7K |
| May 22, 2025 | Daniel G Kaye
Director
|
Sell | 500 | $141.2K |
| May 20, 2025 | Jonathan L Marcus
General Counsel
|
Sell | 390 | $108.2K |
| May 19, 2025 | Phyllis M Lockett
Director
|
Sell | 1.1K | $294.6K |
| May 15, 2025 | Charles P Carey
Director
|
Sell | 3.0K | $817.7K |
| May 15, 2025 | Martin J Gepsman
Director
|
Sell | 300 | $82.0K |
| May 5, 2025 | Derek Louis Sammann
Officer
|
Sell | 4.7K | $1.3M |
| Apr 29, 2025 | Dennis A Suskind
Director
|
Sell | 1.0K | $271.3K |
Source: TwelveData, from SEC Form 4 filings
CME stock forecast: questions people ask
Answered from the figures on this page, as of October 27, 2026.